WBR0871: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) Created page with "{{WBRQuestion |QuestionAuthor={{Rim}} |ExamType=USMLE Step 1 |MainCategory=Immunology |SubCategory=General Principles |MainCategory=Immunology |SubCategory=General Principles ..." |
Rim Halaby (talk | contribs) No edit summary |
||
Line 21: | Line 21: | ||
|SubCategory=General Principles | |SubCategory=General Principles | ||
|Prompt=A 34 year old woman diagnosed with HIV 6 months ago with latest CD4 count of 222 presents to the HIV clinic for follow-up. The patient had been doing well, but complains of difficulty losing weight despite proper exercise and diet. On physical exam, the physician notices significant fat loss in the face, arms and legs with marked abdominal obesity. He also notes fat collection in her upper back in close proximity to her neck. Which of the following medications can explain the patient's current presentation? | |Prompt=A 34 year old woman diagnosed with HIV 6 months ago with latest CD4 count of 222 presents to the HIV clinic for follow-up. The patient had been doing well, but complains of difficulty losing weight despite proper exercise and diet. On physical exam, the physician notices significant fat loss in the face, arms and legs with marked abdominal obesity. He also notes fat collection in her upper back in close proximity to her neck. Which of the following medications can explain the patient's current presentation? | ||
|Explanation=Lipodystrophy is a condition involving the adipose tissue that leads to loss of fat in certain areas on the body with accumulation of fat in other locations. In the context of HIV, some form of lipodystophy occurs in around 15-20% of patients on protease inhibitor therapy although the exact mechanism is unknown. Patients can have manifestations resembling Cushing syndrome. Patients usually present with fat loss in face and extremities with central fat accumulation manifesting as abdominal obesity and "buffalo hump"-like fat deposits in the upper back. Protease inhibitor associated lipodystrophy usually does not resolve after the agent is discontinued. | |||
Educational objective: An important side effect of protease inhibitors is lipodystrophy. | |||
Reference: | |||
Martínez E, Mocroft A, García-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. The Lancet. 2001;357(9256):592-598. | |||
|AnswerA=Saquinavir | |AnswerA=Saquinavir | ||
|AnswerAExp=Saquinavir is a protease inhibitor that can sometimes lead to lipodystrophy in patients on HAART therapy. | |||
|AnswerB=Tenofovir | |AnswerB=Tenofovir | ||
|AnswerBExp=Tenofovir is a NRTI and usually does not cause lipodystrophy. It is usually associated with bone marrow suppression. | |||
|AnswerC=Nevirapine | |AnswerC=Nevirapine | ||
|AnswerCExp=Nevirapine is a NNRTI and usually does not cause lipodystrophy. | |||
|AnswerD=Raltegravir | |AnswerD=Raltegravir | ||
|AnswerDExp=Raltegravir is an integrase inhibitor and usually does not cause lipodystrophy. | |||
|AnswerE=Zidovudine | |AnswerE=Zidovudine | ||
|AnswerEExp=Zidovudine is a NRTI and usually does not cause lipodystrophy. It is usually associated with bone marrow suppression. | |||
|RightAnswer=A | |RightAnswer=A | ||
|WBRKeyword=Lipodystrophy, Protease inhibitors | |WBRKeyword=Lipodystrophy, Protease inhibitors | ||
|Approved=No | |Approved=No | ||
}} | }} |
Revision as of 10:26, 7 November 2013
Author | [[PageAuthor::Rim Halaby, M.D. [1]]] |
---|---|
Exam Type | ExamType::USMLE Step 1 |
Main Category | MainCategory::Immunology |
Sub Category | SubCategory::General Principles |
Prompt | [[Prompt::A 34 year old woman diagnosed with HIV 6 months ago with latest CD4 count of 222 presents to the HIV clinic for follow-up. The patient had been doing well, but complains of difficulty losing weight despite proper exercise and diet. On physical exam, the physician notices significant fat loss in the face, arms and legs with marked abdominal obesity. He also notes fat collection in her upper back in close proximity to her neck. Which of the following medications can explain the patient's current presentation?]] |
Answer A | AnswerA::Saquinavir |
Answer A Explanation | AnswerAExp::Saquinavir is a protease inhibitor that can sometimes lead to lipodystrophy in patients on HAART therapy. |
Answer B | AnswerB::Tenofovir |
Answer B Explanation | AnswerBExp::Tenofovir is a NRTI and usually does not cause lipodystrophy. It is usually associated with bone marrow suppression. |
Answer C | AnswerC::Nevirapine |
Answer C Explanation | AnswerCExp::Nevirapine is a NNRTI and usually does not cause lipodystrophy. |
Answer D | AnswerD::Raltegravir |
Answer D Explanation | AnswerDExp::Raltegravir is an integrase inhibitor and usually does not cause lipodystrophy. |
Answer E | AnswerE::Zidovudine |
Answer E Explanation | AnswerEExp::Zidovudine is a NRTI and usually does not cause lipodystrophy. It is usually associated with bone marrow suppression. |
Right Answer | RightAnswer::A |
Explanation | [[Explanation::Lipodystrophy is a condition involving the adipose tissue that leads to loss of fat in certain areas on the body with accumulation of fat in other locations. In the context of HIV, some form of lipodystophy occurs in around 15-20% of patients on protease inhibitor therapy although the exact mechanism is unknown. Patients can have manifestations resembling Cushing syndrome. Patients usually present with fat loss in face and extremities with central fat accumulation manifesting as abdominal obesity and "buffalo hump"-like fat deposits in the upper back. Protease inhibitor associated lipodystrophy usually does not resolve after the agent is discontinued.
Martínez E, Mocroft A, García-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. The Lancet. 2001;357(9256):592-598. |
Approved | Approved::No |
Keyword | WBRKeyword::Lipodystrophy, WBRKeyword::Protease inhibitors |
Linked Question | Linked:: |
Order in Linked Questions | LinkedOrder:: |